Nature Communications (May 2022)
Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro
- Leiping Zeng,
- Yanxia Liu,
- Xammy Huu Nguyenla,
- Timothy R. Abbott,
- Mengting Han,
- Yanyu Zhu,
- Augustine Chemparathy,
- Xueqiu Lin,
- Xinyi Chen,
- Haifeng Wang,
- Draven A. Rane,
- Jordan M. Spatz,
- Saket Jain,
- Arjun Rustagi,
- Benjamin Pinsky,
- Adrianna E. Zepeda,
- Anastasia P. Kadina,
- John A. Walker,
- Kevin Holden,
- Nigel Temperton,
- Jennifer R. Cochran,
- Annelise E. Barron,
- Michael D. Connolly,
- Catherine A. Blish,
- David B. Lewis,
- Sarah A. Stanley,
- Marie F. La Russa,
- Lei S. Qi
Affiliations
- Leiping Zeng
- Department of Bioengineering, Stanford University
- Yanxia Liu
- Department of Bioengineering, Stanford University
- Xammy Huu Nguyenla
- Department of Molecular and Cellular Biology, University of California
- Timothy R. Abbott
- Department of Bioengineering, Stanford University
- Mengting Han
- Department of Bioengineering, Stanford University
- Yanyu Zhu
- Department of Bioengineering, Stanford University
- Augustine Chemparathy
- Department of Bioengineering, Stanford University
- Xueqiu Lin
- Department of Bioengineering, Stanford University
- Xinyi Chen
- Department of Bioengineering, Stanford University
- Haifeng Wang
- Department of Bioengineering, Stanford University
- Draven A. Rane
- Department of Bioengineering, Stanford University
- Jordan M. Spatz
- Department of Pediatrics, Stanford University
- Saket Jain
- University of California San Francisco
- Arjun Rustagi
- Department of Medicine, Stanford University
- Benjamin Pinsky
- Department of Medicine, Stanford University
- Adrianna E. Zepeda
- Synthego Corporation
- Anastasia P. Kadina
- Synthego Corporation
- John A. Walker
- Synthego Corporation
- Kevin Holden
- Synthego Corporation
- Nigel Temperton
- Viral Pseudotype Unit, Medway School of Pharmacy
- Jennifer R. Cochran
- Department of Bioengineering, Stanford University
- Annelise E. Barron
- Department of Bioengineering, Stanford University
- Michael D. Connolly
- Lawrence Berkeley National Laboratory
- Catherine A. Blish
- Department of Medicine, Stanford University
- David B. Lewis
- Department of Pediatrics, Stanford University
- Sarah A. Stanley
- Department of Molecular and Cellular Biology, University of California
- Marie F. La Russa
- Department of Bioengineering, Stanford University
- Lei S. Qi
- Department of Bioengineering, Stanford University
- DOI
- https://doi.org/10.1038/s41467-022-30546-7
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 16
Abstract
A major challenge in coronavirus vaccination and treatment is to counteract rapid viral evolution and mutations. Here the authors show that CRISPR-Cas13d can be used as a broad-spectrum antiviral to inhibit human coronaviruses, including new SARS-CoV-2 variants, combined with small molecule drugs for an enhanced antiviral effect in human primary cells.
